Press Detail

/
PRESS RELEASE

Biotest receives marketing authorisation for Albiomin^(R) in Brazil and approval for commissioning of expanded albumin production

- Marketing approval granted for albumin in Brazil

- Albumin production capacity doubled from 21 to 42 tons in Dreieich, Germany

Dreieich, Germany, 20 December 2013. Biotest Farmaceutica Ltda., Brazil, a 100% subsidiary of Biotest AG, has announced that it has received marketing approval for Albiomin^(R) (human albumin).

Human albumin is used for stabilization of the blood circulation in severe diseases such as burns as well as chronic diseases of the liver and kidneys or complications associated with protein loss. Currently Biotest is represented on the Brazilian market with its hyperimmunoglobulin preparation Hepatect^(R) CP for the prophylaxis of hepatitis B infections, in partcicular re-infections after liver transplantation, as well as with Megalotect^(R), a hyperimmunoglobulin preparation for the prophylaxis of cytomegalovirus infection for patients undergoing an immuno-suppressive therapy.

Biotest plans to gradually expand the portfolio of products marketed in Brazil. Latin America is one of the largest economic regions of the future. Strong sales and income growth are expected over the medium term from new marketing approvals for immunoglobulins.

Brazil is the fifth largest country in the world by population (around 200 million), which continues to grow. The market for plasma proteins (without recombinant coagulation factors) has a volume of USD 400 million in 2013 (approx. 6% annual growth is expected). Brazil also represents a large transplant market (more than 1,500 liver transplantations in 2011). Given the relatively high incidence (infection rate) of hepatitis B, Biotest's corresponding immunoglobulin portfolio is an excellent response to the country's healthcare needs.

At the same time of the marketing authorization of Albiomin^(R) in Brazil, Biotest announced the commissioning of its albumin plant in Dreieich, which will double the albumin capacity at the Dreieich/Germany location.
The expansion of Biotest's human albumin production capacity has been initiated at Dreieich in August 2011 for an investment of EUR 6.3 million.
The expansion will increase the albumin production capacity in Dreieich from approx. 21 to 42 tons. Approval of the facility was granted in the meantime by the regional authorities in Darmstadt.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has about 1.900 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart